

10/540359
CASE PA4-32832A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV524615550US
Express Mail Label Number

June 23, 2005
Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

23 JUN 2005

IN RE PCT NATIONAL STAGE APPLICATION OF
ALTMANN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/14741

FILED: 22 DECEMBER 2003

U.S. APPLICATION NO: Not Yet Assigned

35 USC §371 DATE:

FOR: DERIVATIVES OF ARYL-QUINAZOLINE/ARYL-2-AMINO-PHENYL
METHANONE WHICH PROMOTE THE RELEASE OF PARATHYROID
HORMONE

MS: Amendment
Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/14741, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7859
Date: June 23, 2005



Susan Hess
Attorney for Applicants
Reg. No. 37,350

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

10/5/0359
ATTY BOOK
PA 3332A
APPLICATION NO.
Not Yet Assigned
APPLICANT
ALTMANN ET AL.
FILING DATE
Herewith

Group

JC20 Rec'd PCT/PTO 23 JUN 2005

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE |
|---------------------|----|-----------------|---------|---------------------------|-------|----------|-------------|
| | AA | 4,387,223 | 6/7/83 | Yamamoto Michihiro et al. | | | |
| | AB | 3,812,257 | 5/21/74 | Inaha et al. | | | |
| | AC | 5,773,663 | 6/30/98 | Rehnig et al. | | | |
| | AD | 5,856,503 | 1/5/99 | Maerki et al. | | | |
| | AE | 3,925,548 | 12/9/75 | Pfeffingen | | | |
| | AF | 6,211,244 | 4/3/01 | Delmar et al. | | | |
| | AG | | | | | | |
| | AH | | | | | | |
| | AI | | | | | | |
| | AJ | | | | | | |
| | AK | | | | | | |
| | AL | | | | | | |

FOREIGN PATENT DOCUMENTS

| | | DOCUMENT NUMBER | DATE | OFFICE | CLASS | SUBCLASS | TRANSLATION | |
|--|----|-----------------|----------|---------------|-------|----------|--------------------------|--------------------------|
| | | | | | | | YES | NO |
| | AM | CH 612 186 | 7/13/79 | Swiss | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AN | GB 1 353 789 | 5/22/74 | Great Britain | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AO | WO 02/24683 | 3/28/02 | WIPO | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AP | WO 02/102782 | 12/27/02 | WIPO | | | <input type="checkbox"/> | <input type="checkbox"/> |
| | AQ | | | | | | <input type="checkbox"/> | <input type="checkbox"/> |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | | |
|--|----|---|
| | AR | Russell et al., "Synthesis and Renal Vasodilator Activity of Substituted '4-alkyl(aryl)-2-oxoquinazolin-1-ylalkanoic Acids", European Journal of Medicinal Chemistry, Vol. 27, No. 3, pp. 277-284, (1992) |
| | AS | Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002935850 & Miyagishi et al, "General Pharmaceutical Studies on Ciproquazone (SL-573) and its Metabolites" OYL YAKURI, vol. 18, No. 1, pp. 9-22 (1979) |
| | AT | Masai, et al, "Carbon-13 Nuclear Magnetic Resonance Studies of Anti-Inflammatory 2(1H)-Quinazolinones", Chemical & Pharmaceutical Bulletin, Vol. 25, No. 11, pp. 3018-3022, (1977) |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

10/50359
ATTY. DOKK
PA 33332A
APPLICATION NO.
Not Yet Assigned
APPLICANT
ALTMANN ET AL.
FILING DATE
Herewith

Group

JC20 Rec'd PCT/PTO 23 JUN 2005

EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

| | |
|----|---|
| DA | Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280289 retrieved from STN accession no. 503745 rn: 37554-38-4 & Mardente et al, "GLC-ECD Determination of 1-(2-Hydroxyethyl)-3-Hydroxy-7-Chloro-1,3-Dihydro-5-(0-Fluorophenyl)-2H-1,4-Benzodiazepin-2-one (SAS 643) in Plasma and Urine and Identification of its main Biotransformation Products" Therapeutic Drug Monitoring, Vol. 3, No. 4, pp. 351-356 (1981) |
| DB | Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280290 retrieved from STN accession no. 1142 database accession no. 1994:244939 rn: 154374-68-2P; 154374-67-1 & M. I. Jaeda at al, "Synthesis of Some Novel 2(1H)-Quinazolinones and 2-Thioxoanalogues from Newly Synthesized 1-acyl-3-alkoxyphenylureas and Tioureas", Journal of Chemical Technology and Biotechnology, Vol. 58, No. 4, pp. 391-394, (1993) |
| DC | Database Caplus 'Online! Chemical Abstracts Service, Columbus, Ohio: XP002280291 retrieved from STN accession no. 1277 database accession no. 1981:461773 rn 78350-38-6 & JP 55 143959 (Shionogi and Co.) 1980 |
| DD | Database Crossfire Beilstein 'Online! Beilstein Institut zur Forderung der Chemischen Wissenschaften, XP002280292 Database Accession no. 6810088 & Berger et al., ACTA Crystallogr. Sect. C: Cryst. Struct. Commun, Vol. 50, pp. 773-775, (1994) |
| DE | |
| DF | |
| DG | |
| DH | |
| DI | |
| DJ | |
| DK | |
| DL | |
| DM | |
| DN | |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant